Pirtobrutinib outperforms bendamustine plus rituximab for previously untreated CLL/SLL
In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when compared with bendamustine ...
Dec 9, 2025
0
7









